Therapy-related Virus Reactivation in Lymphoma Patients with Hepatitis B Virus Infection--Review.
10.7534/j.issn.1009-2137.2016.01.051
- Author:
Zhuo LI
1
;
Zi-Jian LI
1
;
Ya-Ming XI
2
Author Information
1. Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.
2. Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China. E-mail: xiyaming02@163.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Hepatitis B;
complications;
drug therapy;
prevention & control;
Hepatitis B Surface Antigens;
Hepatitis B virus;
drug effects;
physiology;
Humans;
Lymphoma;
drug therapy;
virology;
Risk Factors;
Virus Activation;
drug effects
- From:
Journal of Experimental Hematology
2016;24(1):266-270
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of HBV infection in lymphoma patients is much higher than that in the general normal population. HBV reactivation caused by treatment is one of the common complications in considerable amount of lymphoma patients, which can induce fatal fulminating hepatitis in severe cases. The HBV reactivation in lymphoma patients is related to multiple factors, such as age, sex, HBV infectious state, HBV genotypes and gene mutations, and antitumor drugs. It's necessary to strengthen monitoring, prevention and treatment to HBV reactivation in the process of dealing with lymphoma. This review focuses on the epidemiological characteristics of lymphoma and HBV, as well as the risk factors, morbidity, pathogenesis, clinical feature, suggestion on prevention and treatment of HBV reactivation.
